E
Antibe Therapeutics Inc.
ATBPF
$0.2156
$0.025613.47%
E
Sell
4/1/2025Downgrade
Antibe Therapeutics Inc. (ATBPF) was downgraded to E- from D- on 4/1/2025 due to a decline in the volatility index.
Antibe Therapeutics Inc. (ATBPF) was downgraded to E- from D- on 4/1/2025 due to a decline in the volatility index.
D
Sell
1/13/2025Upgraded
Antibe Therapeutics Inc. (ATBPF) was upgraded to D- from E+ on 1/13/2025 due to an increase in the volatility index and total return index.
Antibe Therapeutics Inc. (ATBPF) was upgraded to D- from E+ on 1/13/2025 due to an increase in the volatility index and total return index.
E
Sell
12/27/2024Downgrade
Antibe Therapeutics Inc. (ATBPF) was downgraded to E+ from D- on 12/27/2024 due to a decline in the volatility index.
Antibe Therapeutics Inc. (ATBPF) was downgraded to E+ from D- on 12/27/2024 due to a decline in the volatility index.
D
Sell
12/4/2024Upgraded
Antibe Therapeutics Inc. (ATBPF) was upgraded to D- from E+ on 12/4/2024 due to an increase in the volatility index.
Antibe Therapeutics Inc. (ATBPF) was upgraded to D- from E+ on 12/4/2024 due to an increase in the volatility index.
E
Sell
4/17/2024Downgrade
Antibe Therapeutics Inc. (ATBPF) was downgraded to E+ from D- on 4/17/2024 due to a decline in the total return index and volatility index.
Antibe Therapeutics Inc. (ATBPF) was downgraded to E+ from D- on 4/17/2024 due to a decline in the total return index and volatility index.
D
Sell
4/1/2024Upgraded
Antibe Therapeutics Inc. (ATBPF) was upgraded to D- from E+ on 4/1/2024 due to an increase in the volatility index and valuation index.
Antibe Therapeutics Inc. (ATBPF) was upgraded to D- from E+ on 4/1/2024 due to an increase in the volatility index and valuation index.
E
Sell
3/14/2024Downgrade
Antibe Therapeutics Inc. (ATBPF) was downgraded to E+ from D- on 3/14/2024 due to a decline in the volatility index and solvency index. The quick ratio declined from 9.98 to 9.14.
Antibe Therapeutics Inc. (ATBPF) was downgraded to E+ from D- on 3/14/2024 due to a decline in the volatility index and solvency index. The quick ratio declined from 9.98 to 9.14.
D
Sell
1/4/2024Upgraded
Antibe Therapeutics Inc. (ATBPF) was upgraded to D- from E+ on 1/4/2024 due to a large increase in the total return index and volatility index.
Antibe Therapeutics Inc. (ATBPF) was upgraded to D- from E+ on 1/4/2024 due to a large increase in the total return index and volatility index.
E
Sell
3/14/2023Downgrade
Antibe Therapeutics Inc. (ATBPF) was downgraded to E+ from D on 03/14/2023.
Antibe Therapeutics Inc. (ATBPF) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/15/2023Upgraded
Antibe Therapeutics Inc. (ATBPF) was upgraded to D from E+ on 2/15/2023 due to an increase in the growth index and total return index. Earnings per share increased from -$0.0894 to -$0.0608, EBIT increased 31.12% from -$4.99M to -$3.43M, and operating cash flow increased 26.79% from -$3.63M to -$2.66M.
Antibe Therapeutics Inc. (ATBPF) was upgraded to D from E+ on 2/15/2023 due to an increase in the growth index and total return index. Earnings per share increased from -$0.0894 to -$0.0608, EBIT increased 31.12% from -$4.99M to -$3.43M, and operating cash flow increased 26.79% from -$3.63M to -$2.66M.
E
Sell
2/8/2023Downgrade
Antibe Therapeutics Inc. (ATBPF) was downgraded to E+ from D- on 2/8/2023 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 13.29 to 9.58.
Antibe Therapeutics Inc. (ATBPF) was downgraded to E+ from D- on 2/8/2023 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 13.29 to 9.58.
D
Sell
7/1/2022Downgrade
Antibe Therapeutics Inc. (ATBPF) was downgraded to D- from D on 7/1/2022 due to a noticeable decline in the growth index, total return index and solvency index. Operating cash flow declined 103.22% from -$1.46M to -$2.98M, the quick ratio declined from 16.53 to 11.91, and earnings per share declined from -$0.0743 to -$0.0795.
Antibe Therapeutics Inc. (ATBPF) was downgraded to D- from D on 7/1/2022 due to a noticeable decline in the growth index, total return index and solvency index. Operating cash flow declined 103.22% from -$1.46M to -$2.98M, the quick ratio declined from 16.53 to 11.91, and earnings per share declined from -$0.0743 to -$0.0795.
D
Sell
5/16/2022Upgraded
Antibe Therapeutics Inc. (ATBPF) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index.
Antibe Therapeutics Inc. (ATBPF) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index.
E
Sell
5/13/2022Downgrade
Antibe Therapeutics Inc. (ATBPF) was downgraded to E+ from D on 05/13/2022.
Antibe Therapeutics Inc. (ATBPF) was downgraded to E+ from D on 05/13/2022.
D
Sell
5/4/2022Upgraded
Antibe Therapeutics Inc. (ATBPF) was upgraded to D from E+ on 05/04/2022.
Antibe Therapeutics Inc. (ATBPF) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Antibe Therapeutics Inc. (ATBPF) was downgraded to E+ from D on 05/01/2022.
Antibe Therapeutics Inc. (ATBPF) was downgraded to E+ from D on 05/01/2022.
D
Sell
4/21/2022Upgraded
Antibe Therapeutics Inc. (ATBPF) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index and total return index.
Antibe Therapeutics Inc. (ATBPF) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index and total return index.
E
Sell
4/20/2022Downgrade
Antibe Therapeutics Inc. (ATBPF) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index.
Antibe Therapeutics Inc. (ATBPF) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index.
D
Sell
2/16/2022Upgraded
Antibe Therapeutics Inc. (ATBPF) was upgraded to D from D- on 2/16/2022 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$0.1332 to -$0.0743, and EBIT increased 37.6% from -$6.66M to -$4.15M.
Antibe Therapeutics Inc. (ATBPF) was upgraded to D from D- on 2/16/2022 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$0.1332 to -$0.0743, and EBIT increased 37.6% from -$6.66M to -$4.15M.
D
Sell
11/17/2021Downgrade
Antibe Therapeutics Inc. (ATBPF) was downgraded to D- from D on 11/17/2021 due to a large decline in the growth index, solvency index and total return index. EBIT declined 29.45% from -$5.14M to -$6.66M, earnings per share declined from -$0.1079 to -$0.1396, and operating cash flow declined 25.7% from -$4.02M to -$5.05M.
Antibe Therapeutics Inc. (ATBPF) was downgraded to D- from D on 11/17/2021 due to a large decline in the growth index, solvency index and total return index. EBIT declined 29.45% from -$5.14M to -$6.66M, earnings per share declined from -$0.1079 to -$0.1396, and operating cash flow declined 25.7% from -$4.02M to -$5.05M.
D
Sell
11/9/2021Upgraded
Antibe Therapeutics Inc. (ATBPF) was upgraded to D from E+ on 11/09/2021.
Antibe Therapeutics Inc. (ATBPF) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Antibe Therapeutics Inc. (ATBPF) was downgraded to E+ from D on 11/8/2021 due to a major decline in the total return index and volatility index.
Antibe Therapeutics Inc. (ATBPF) was downgraded to E+ from D on 11/8/2021 due to a major decline in the total return index and volatility index.
D
Sell
8/3/2021Downgrade
Antibe Therapeutics Inc. (ATBPF) was downgraded to D from D+ on 8/3/2021 due to a decline in the volatility index and total return index.
Antibe Therapeutics Inc. (ATBPF) was downgraded to D from D+ on 8/3/2021 due to a decline in the volatility index and total return index.
D
Sell
7/1/2021Upgraded
Antibe Therapeutics Inc. (ATBPF) was upgraded to D+ from D on 7/1/2021 due to a noticeable increase in the solvency index, valuation index and growth index. The quick ratio increased from 3.55 to 19.94, operating cash flow increased 394.07% from -$5.05M to $14.84M, and debt to equity declined from 0.01 to 0.
Antibe Therapeutics Inc. (ATBPF) was upgraded to D+ from D on 7/1/2021 due to a noticeable increase in the solvency index, valuation index and growth index. The quick ratio increased from 3.55 to 19.94, operating cash flow increased 394.07% from -$5.05M to $14.84M, and debt to equity declined from 0.01 to 0.
D
Sell
5/1/2020Upgraded
Antibe Therapeutics Inc. (ATBPF) was upgraded to D from D- on 5/1/2020 due to a significant increase in the total return index, growth index and solvency index. Earnings per share increased from -$0.0144 to -$0.0114, total revenue increased 15.12% from $1.72M to $1.98M, and EBIT increased 13.88% from -$3.67M to -$3.16M.
Antibe Therapeutics Inc. (ATBPF) was upgraded to D from D- on 5/1/2020 due to a significant increase in the total return index, growth index and solvency index. Earnings per share increased from -$0.0144 to -$0.0114, total revenue increased 15.12% from $1.72M to $1.98M, and EBIT increased 13.88% from -$3.67M to -$3.16M.
D
Sell
3/3/2017Downgrade
Antibe Therapeutics Inc. (ATBPF) was downgraded to D- from D on 3/3/2017 due to a decline in the efficiency index, growth index and solvency index. Earnings per share declined from -$0.0095 to -$0.015, net income declined 56.33% from -$890.5 to -$1.39M, and EBIT declined 40.9% from -$750.8 to -$1.06M.
Antibe Therapeutics Inc. (ATBPF) was downgraded to D- from D on 3/3/2017 due to a decline in the efficiency index, growth index and solvency index. Earnings per share declined from -$0.0095 to -$0.015, net income declined 56.33% from -$890.5 to -$1.39M, and EBIT declined 40.9% from -$750.8 to -$1.06M.
D
Sell
8/31/2016Upgraded
Antibe Therapeutics Inc. (ATBPF) was upgraded to D from D- on 8/31/2016 due to an increase in the efficiency index, volatility index and total return index. Total capital increased 3.54% from $6.46M to $6.69M.
Antibe Therapeutics Inc. (ATBPF) was upgraded to D from D- on 8/31/2016 due to an increase in the efficiency index, volatility index and total return index. Total capital increased 3.54% from $6.46M to $6.69M.
D
Sell
8/3/2016Downgrade
Antibe Therapeutics Inc. (ATBPF) was downgraded to D- from D on 8/3/2016 due to a significant decline in the efficiency index, volatility index and total return index.
Antibe Therapeutics Inc. (ATBPF) was downgraded to D- from D on 8/3/2016 due to a significant decline in the efficiency index, volatility index and total return index.
D
Sell
3/2/2016Upgraded
Antibe Therapeutics Inc. (ATBPF) was upgraded to D from D- on 3/2/2016 due to a significant increase in the efficiency index, growth index and valuation index. Total capital increased 1,698.29% from $351.9 to $6.33M, and operating cash flow increased 35.47% from -$548.9 to -$743.6.
Antibe Therapeutics Inc. (ATBPF) was upgraded to D from D- on 3/2/2016 due to a significant increase in the efficiency index, growth index and valuation index. Total capital increased 1,698.29% from $351.9 to $6.33M, and operating cash flow increased 35.47% from -$548.9 to -$743.6.
D
Sell
7/1/2015Upgraded
Antibe Therapeutics Inc. (ATBPF) was upgraded to D- from E on 7/1/2015 due to an increase in the total return index and volatility index.
Antibe Therapeutics Inc. (ATBPF) was upgraded to D- from E on 7/1/2015 due to an increase in the total return index and volatility index.
E
Sell
4/16/2015Downgrade
Antibe Therapeutics Inc. (ATBPF) was downgraded to E from E+ on 4/16/2015 due to a decline in the valuation index.
Antibe Therapeutics Inc. (ATBPF) was downgraded to E from E+ on 4/16/2015 due to a decline in the valuation index.
E
Sell
4/1/2015Upgraded
Antibe Therapeutics Inc. (ATBPF) was upgraded to E+ from E on 4/1/2015 due to an increase in the valuation index and growth index.
Antibe Therapeutics Inc. (ATBPF) was upgraded to E+ from E on 4/1/2015 due to an increase in the valuation index and growth index.
E
Sell
1/27/2015Upgraded
Antibe Therapeutics Inc. (ATBPF) was upgraded to E from E- on 1/27/2015 due to an increase in the total return index and valuation index.
Antibe Therapeutics Inc. (ATBPF) was upgraded to E from E- on 1/27/2015 due to an increase in the total return index and valuation index.
E
Sell
1/5/2015None
Antibe Therapeutics Inc. (ATBPF) was downgraded to E- from U on 01/05/2015.
Antibe Therapeutics Inc. (ATBPF) was downgraded to E- from U on 01/05/2015.
OTC PK
04/08/2024 3:46PM Eastern
Quotes delayed
